Assessment of Type 1 Diabetes Patients' Sialic Acid Binding Immunoglobulin-Like Lectin-1 Level

Document Type : Original Article

Authors

University of Kufa / Faculty of Sciences, Najaf, Iraq

Abstract

Type 1 diabetes is an autoimmune genetic disease. This study aimed to determine the analytical estimation of SBI-like lectin-1 levels in the serum of type 1 diabetes patients and their relationship to hyperglycemia. Methods: This study was conducted on type 1 diabetes patients who visited the Diabetes and Endocrinology Center in Najaf Governorate, Iraq, between November 1, 2023, and February 1, 2024. The study also included sixty (60) patients (40 males and 20 females) and thirty (30) controls (apparently healthy), and glycated hemoglobin (HbA1c) values ​​ among individuals with diabetes as opposed to the control groups, and a significant decline (P < 0.05) in Siglec-1 levels in diabetic patients compared to the control groups. The present results indicated a decrease in sialic acid-like lectin-binding immunoglobulin-1 (Siglec-1) in the serum of type 1 diabetic patients compared to the control group. The study showed a significant decrease (P < 0.05) in Ceglic-1 levels in patients who received treatment. Male type 1 diabetes patients showed lower levels (P < 0.05) of Siglec-1 compared to female patients. The current study concludes that Ceglic-1 is a prognostic marker used to predict type 1 diabetes, especially in patients newly diagnosed at a younger age and with a shorter disease duration.

Keywords

Files

Share

How to cite

Statistics